The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

Christina Justenhoven; Ofure Obazee; Stefan Winter; Fergus J. Couch; Janet E. Olson; Per Hall; Ulf Hannelius; Jingmei Li; Keith Humphreys; Gianluca Severi; Graham Giles; Melissa Southey; Laura Baglietto; Peter A. Fasching; Matthias W. Beckmann; Arif B. Ekici; Ute Hamann; Christian Baisch; Volker Harth; Sylvia Rabstein; Anne Lotz; Beate Pesch; Thomas Brüning; Yon Dschun Ko; Hiltrud Brauch

doi:10.1007/s10549-011-1827-1

The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

Christina Justenhoven, Ofure Obazee, Stefan Winter, Fergus J. Couch, Janet E. Olson, Per Hall, Ulf Hannelius, Jingmei Li, Keith Humphreys, Gianluca Severi, Graham Giles, Melissa Southey, Laura Baglietto, Peter A. Fasching, Matthias W. Beckmann, Arif B. Ekici, Ute Hamann, Christian Baisch, Volker Harth, Sylvia RabsteinAnne Lotz, Beate Pesch, Thomas Brüning, Yon Dschun Ko, Hiltrud Brauch

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	347-350
Number of pages	4
Journal	Breast Cancer Research and Treatment
Volume	131
Issue number	1
DOIs	https://doi.org/10.1007/s10549-011-1827-1
State	Published - Jan 2012

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10549-011-1827-1

Cite this

Justenhoven, C., Obazee, O., Winter, S., Couch, F. J., Olson, J. E., Hall, P., Hannelius, U., Li, J., Humphreys, K., Severi, G., Giles, G., Southey, M., Baglietto, L., Fasching, P. A., Beckmann, M. W., Ekici, A. B., Hamann, U., Baisch, C., Harth, V., ... Brauch, H. (2012). The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Research and Treatment, 131(1), 347-350. https://doi.org/10.1007/s10549-011-1827-1

Justenhoven, C, Obazee, O, Winter, S, Couch, FJ , Olson, JE, Hall, P, Hannelius, U, Li, J, Humphreys, K, Severi, G, Giles, G, Southey, M, Baglietto, L, Fasching, PA, Beckmann, MW, Ekici, AB, Hamann, U, Baisch, C, Harth, V, Rabstein, S, Lotz, A, Pesch, B, Brüning, T, Ko, YD & Brauch, H 2012, 'The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant', Breast Cancer Research and Treatment, vol. 131, no. 1, pp. 347-350. https://doi.org/10.1007/s10549-011-1827-1

@article{35b124cdcd9246649c1d7091f3f3fea3,

title = "The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant",

author = "Christina Justenhoven and Ofure Obazee and Stefan Winter and Couch, {Fergus J.} and Olson, {Janet E.} and Per Hall and Ulf Hannelius and Jingmei Li and Keith Humphreys and Gianluca Severi and Graham Giles and Melissa Southey and Laura Baglietto and Fasching, {Peter A.} and Beckmann, {Matthias W.} and Ekici, {Arif B.} and Ute Hamann and Christian Baisch and Volker Harth and Sylvia Rabstein and Anne Lotz and Beate Pesch and Thomas Br{\"u}ning and Ko, {Yon Dschun} and Hiltrud Brauch",

note = "Funding Information: Acknowledgments This study and the GENICA study was supported by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Institute of Pathology, Medical Faculty of the University of Bonn, Deutsches Krebsforschungszentrum, Heidelberg, and the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany. The SASBAC study was supported by the M{\"a}rit and Hans Rausing{\textquoteright}s Initiative Against Breast Cancer, the National Institutes of Health (RO1 CA58427), the Agency for Science, Technology and Research (A*STAR; Singapore), and the Swedish Research Council. J Li was a recipient of the A*STAR Graduate Scholarship. KH was supported by the Swedish Research Council (523-2006-972). MSC is a Senior Research Fellow of the Australian National Health and Medical Research Council and a Victorian Breast Cancer Research Consortium Group Leader. MCCS is supported by Cancer Council Victoria and by NHMRC (Grants 209057, 251533, 396414, 504711, 504715). The BBCC study was supported by the ELAN program of the University Hospital Erlangen. All authors disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations.",

year = "2012",

month = jan,

doi = "10.1007/s10549-011-1827-1",

language = "English (US)",

volume = "131",

pages = "347--350",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

AU - Justenhoven, Christina

AU - Obazee, Ofure

AU - Winter, Stefan

AU - Couch, Fergus J.

AU - Olson, Janet E.

AU - Hall, Per

AU - Hannelius, Ulf

AU - Li, Jingmei

AU - Humphreys, Keith

AU - Severi, Gianluca

AU - Giles, Graham

AU - Southey, Melissa

AU - Baglietto, Laura

AU - Fasching, Peter A.

AU - Beckmann, Matthias W.

AU - Ekici, Arif B.

AU - Hamann, Ute

AU - Baisch, Christian

AU - Harth, Volker

AU - Rabstein, Sylvia

AU - Lotz, Anne

AU - Pesch, Beate

AU - Brüning, Thomas

AU - Ko, Yon Dschun

AU - Brauch, Hiltrud

N1 - Funding Information: Acknowledgments This study and the GENICA study was supported by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Institute of Pathology, Medical Faculty of the University of Bonn, Deutsches Krebsforschungszentrum, Heidelberg, and the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany. The SASBAC study was supported by the Märit and Hans Rausing’s Initiative Against Breast Cancer, the National Institutes of Health (RO1 CA58427), the Agency for Science, Technology and Research (A*STAR; Singapore), and the Swedish Research Council. J Li was a recipient of the A*STAR Graduate Scholarship. KH was supported by the Swedish Research Council (523-2006-972). MSC is a Senior Research Fellow of the Australian National Health and Medical Research Council and a Victorian Breast Cancer Research Consortium Group Leader. MCCS is supported by Cancer Council Victoria and by NHMRC (Grants 209057, 251533, 396414, 504711, 504715). The BBCC study was supported by the ELAN program of the University Hospital Erlangen. All authors disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations.

PY - 2012/1

Y1 - 2012/1

UR - http://www.scopus.com/inward/record.url?scp=84856210137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856210137&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1827-1

DO - 10.1007/s10549-011-1827-1

M3 - Letter

C2 - 22037784

AN - SCOPUS:84856210137

SN - 0167-6806

VL - 131

SP - 347

EP - 350

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this